"Razoxane" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antimitotic agent with immunosuppressive properties.
| Descriptor ID |
D011929
|
| MeSH Number(s) |
D03.383.606.385.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Razoxane".
Below are MeSH descriptors whose meaning is more specific than "Razoxane".
This graph shows the total number of publications written about "Razoxane" by people in this website by year, and whether "Razoxane" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Razoxane" by people in Profiles.
-
Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Dec 15; 59(7):1259-65.
-
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer. 2011 Jun; 47(9):1373-9.
-
Can anthracycline therapy for pediatric malignancies be less cardiotoxic? Curr Oncol Rep. 2010 Nov; 12(6):411-9.
-
Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion. Pediatr Hematol Oncol. 2010 Oct; 27(7):546-57.
-
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol. 2007 Feb 10; 25(5):493-500.
-
Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res. 2005 Sep 15; 65(18):8142-50.
-
Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004 Jun 29; 109(25):3122-31.
-
Dexrazoxane's protection of jejunal crypt cells in the jejunum of C3Hf/Kam mice from doxorubicin-induced toxicity. Cancer Chemother Pharmacol. 2003 Dec; 52(6):477-81.
-
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies. Clin Cancer Res. 2001 Jun; 7(6):1569-76.
-
Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996 Feb; 14(2):362-72.